IL17A and neoplasm: IL23 drives Th17 production of IL17 and can potentiate anti-tumour immunity in established cancers; both cytokines were found to be upregulated in R subgroup mesotheliomas suggesting a possible functional role for this axis in regulating sensitivity to PD1 inhibition in mesothelioma.